BRAF V600E

PD-L1 expression is frequently observed in AM with BRAFV600E mutation, whereas no significant correlation is identified between PD-L1 and the clinicopathological parameters associated with AM. Within the limitation of relatively short follow-up duration, high CD8+T cell infiltration was indicated to be potentially correlated with favorable DFS in AM patients, which needs further verification in cohorts with longer follow-up.

Nanopore sequencing enables rapid, accurate, multidimensional molecular classification of diagnostically intractable CNS tumors using routine FFPE and frozen tissue, achieving high diagnostic resolution in comparison with reference methods while drastically reducing turnaround time and cost, making precision neuropathology feasible beyond quaternary centers.

Patients with high TEPGS exhibited resistance to immunotherapy but responded to a BRAF V600E inhibitor, while TEPGS showed tentative value for predicting cetuximab response and preliminary utility for bevacizumab. Functional assays confirmed ARPC1B as an oncogene. Our findings establish TEPGS as a valuable biomarker for prognostic stratification and tailored therapy selection in CRC.

However, in patients with BRAF-mutated melanomas, those who received BRAF inhibitors exhibited improved survival outcomes in advanced disease stages (p = 0.0025). Our study indicates that BRAF-mutated melanoma patients with distant metastases receiving BRAF inhibitors have significantly improved survival compared to those not receiving targeted therapy, supporting the clinical benefit of BRAF inhibitor use in appropriately selected patients.

These findings support the value of routine IHC-based MMR testing in CRC patients. However, confirmatory molecular testing (e.g., MSI analysis, BRAF V600E mutation, MLH1 promoter methylation, or germline sequencing) is necessary to differentiate sporadic from Lynch syndrome-associated dMMR cases and to fully guide Lynch syndrome screening and immunotherapy decisions.

Prognostic accuracy improved when tumor genotype was combined with the expression of activator of HSP90 ATPase activity 1 (AHSA1) and thioredoxin domain-containing 5 (TXNDC5), involved in ER-associated protein folding. These findings define a distinctive proteomic signature in BRAF-mutated CRC, characterized by dysregulated protein folding associated with ER stress and supporting the development of targeted therapies and more precise prognostic models.

In endometrial cancer, dostarlimab combined with chemotherapy improved PFS in both dMMR/MSI-H and mismatch repair-proficient disease and increased OS overall...Confidence is strongest for PD-1 inhibitors in MSI-H/dMMR tumors, trastuzumab deruxtecan in HER2-low or HER2-positive cancers, and encorafenib-based regimens in BRAF V600E metastatic colorectal cancer. Implementation should include validated assays (including reconfirmation of HER2 status), prioritize earlier treatment lines where gains are greatest, and require vigilant ILD monitoring. Head-to-head trials and assay standardization, especially for tumor mutational burden, remain priorities.

In real-world practice, a meaningful proportion (4%) of mCRC patients experience inconclusive MSI/MMR assessment, with important clinical implications. Both technical and biological factors contribute to diagnostic uncertainty. Integrating orthogonal testing modalities and applying structured adjudication improves classification accuracy and ensures appropriate access to immunotherapy.

Additionally, consistent "Rho GTPase signaling" changes were observed across both proteomic and phosphoproteomic analyses, underscoring the functional reactivation of this pathway in resistant tumors. In summary, these findings reveal molecular signatures of early response and acquired resistance to vemurafenib and offer a valuable resource for future investigation of BRAF-targeted therapy.

P=N/A, N=152, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Active, not recruiting --> Recruiting

These observed frequencies should be interpreted as case-level implementation signals surfaced through routine CGP rather than assay superiority evidence, biological prevalence estimates, or treatment-benefit data. This nationwide, platform-aware benchmark supports practical interpretation of tumor-agnostic eligibility signals in routine CGP practice in Japan.

We report 10-years old child with recurrent PA harboring concurrent BRAFV600E and TP53 mutations, emphasizing the potential biological significance of this dual-mutant genotype. This case supports the growing recognition that specific molecular variants may identify children at increased risk of early tumor regrowth despite initial gross total resection.